Skip to main content
. Author manuscript; available in PMC: 2019 Mar 10.
Published in final edited form as: Ann Neurol. 2018 Mar 10;83(3):544–552. doi: 10.1002/ana.25172

Table 2. Differences in levels of complement components in ADEs and NDEs.

ADEs C5b-C9 TCC C3d C4b Bb Factor B Factor D
Subjects Cntrl AD Cntrl AD Cntrl AD Cntrl AD Cntrl AD Cntrl AD
355 1212 48,705 416,093 64,305 166,151 91,933 252,271 113,321 547,292 1465 5800
NDEs C5b-C9 TCC C3d C4b Bb Factor B Factor D
Subjects Cntrl AD Cntrl AD Cntrl AD Cntrl AD Cntrl AD Cntrl AD
54.2 68.8 1855 11,562 3851 9354 6059 14,624 2055 7128 94.2 306

Cntrl= controls and AD= Alzheimer's disease patients. All values shown are mean pg/ml (values for mean±S.E.M. are in the text of Results or in the legend for Figure 2). All differences between levels of corresponding analytes in ADEs and NDEs are significant with p<0.0001.